Edwards Lifesciences EW Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Europe | $1.62B+21.0% | $1.52B+14.8% | $1.45B+13.4% | $1.38B+11.3% | $1.34B+10.3% | |
| Japan | $363.5M+8.3% | $354.7M+4.4% | $353.1M0.0% | $344.4M-3.4% | $335.6M-6.2% | |
| Rest of World | $679.9M+15.9% | $652.3M+14.0% | $630.1M+12.4% | $611.1M+11.5% | $586.4M+8.0% | |
| United States | $3.64B+11.6% | $3.54B+10.5% | $3.45B+9.9% | $3.35B+9.0% | $3.26B+7.9% | |
| Total other segment items by Business | ||||||
| Europe | $116.4M+4,556% | $66.2M+344% | $41M+371% | $16.9M+483% | $2.5M+127% | |
| Japan | -$11.4M+5.8% | -$10M-47.1% | -$7.2M-28,900% | -$8.7M-212% | -$12.1M-173% | |
| Rest of World | -$24.7M-32.8% | -$26.4M-151% | -$25.5M-268% | -$23.5M-440% | -$18.6M-1,161% | |
| United States | $2.7M+17.4% | $2.5M+4.2% | $2.3M-8.9% | $2.2M-10.2% | $2.3M+1.1% | |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest by Business | ||||||
| Europe | $837M+12.7% | $796.2M+9.8% | $789.9M+11.9% | $760.6M+11.0% | $742.7M+11.7% | |
| Japan | $242.5M+8.5% | $233.8M+9.6% | $234.5M+9.5% | $229.1M+7.4% | $223.6M+7.0% | |
| Rest of World | $310.7M+18.0% | $298.5M+22.8% | $302.5M+24.4% | $287.7M+22.2% | $263.4M+12.5% | |
| United States | $2.4B+9.4% | $2.35B+8.6% | $2.28B+7.9% | $2.24B+8.3% | $2.19B+7.3% | |
| Selling, general, and administrative expenses by Business | ||||||
| Europe | $313.4M+10.1% | $315M+11.5% | $292.9M+7.5% | $287.9M+5.6% | $284.6M+6.7% | |
| Japan | $78M+3.3% | $78.5M-7.8% | $74.6M-7.7% | $74.4M-7.7% | $75.5M-3.9% | |
| Rest of World | $215.5M+18.3% | $209.6M+15.5% | $190.2M+10.1% | $183.8M+7.4% | $182.1M+9.6% | |
| United States | $596.2M+15.5% | $575.3M+15.5% | $547.9M+17.2% | $533.9M+18.8% | $516M+17.3% | |
| Cost of Sales by Business | ||||||
| Europe | $351.5M+14.2% | $340.1M+13.7% | $327.8M+13.9% | $318.1M+12.7% | $307.7M+11.9% | |
| Japan | $54.4M+11.9% | $52.4M+8.9% | $51.2M+7.2% | $49.6M+4.0% | $48.6M+4.0% | |
| Rest of World | $178.4M+11.8% | $170.6M+7.9% | $162.9M+6.0% | $163.1M+11.1% | $159.5M+13.5% | |
| United States | $646.3M+16.9% | $620.3M+13.5% | $614.5M+14.0% | $574M+6.6% | $552.9M+6.6% | |
| Net Sales by Product | ||||||
| Transcatheter Aortic Valve Replacement | $4.64B+11.9% | $4.49B+9.3% | $4.36B+7.8% | $4.24B+6.3% | $4.14B+5.2% | |
| Transcatheter Mitral and Tricuspid Therapies | $610.5M+54.8% | $550.6M+56.4% | $500M+65.0% | $445.9M+68.7% | $394.4M+72.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Edwards Lifesciences break its business down?
- Edwards Lifesciences (EW) reports net sales by business across 4 parts — Europe, Japan, Rest of World and United States. Each is extracted from the segment footnotes and tracked over time.
- Where does Edwards Lifesciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Edwards Lifesciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
